Tag:
Immunosyn
Latest Headlines
Latest Headlines
SEC lays out "tall tales" in $20M biotech securities scam
According to executives at Immunosyn and its controlling shareholder Argyll Biotechnologies, the biotech was onto something truly special. Its lead drug, SF-1019, which had been derived from goat's
C&L: Valeant makes management changes
Valeant Pharmaceuticals International has appointed J. Michael Pearson to the position of chief executive officer following the resignation of Timothy Tyson as president, chief executive officer and
